The FDA issued a fact sheet for healthcare providers on the Emergency Use Authorization for Pfizer’s Paxlovid, which indicates that the EUA has been revised to remove a previous requirement of SARS-CoV-2 viral testing. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE: